Our Services
Medical Information
Helpful Resources
Published on: 7/2/2026
Dupixent for CRSwNP (chronic rhinosinusitis with nasal polyps) costs about $3,100 per 2-mL syringe, with insurance copays ranging from $50 to over $1,000 per injection depending on your plan's formulary, deductible and specialty pharmacy requirements. Financial assistance options—including the Sanofi MyWay program, independent patient foundations, manufacturer savings cards and cost-saving strategies like mail-order pharmacies—can substantially reduce your out-of-pocket expenses.
Key factors to weigh before your next step include eligibility criteria, application tips and timing strategies, all detailed below.
Because CRSwNP symptoms like nasal congestion, loss of smell and facial pressure overlap with many other conditions, confirming what's actually driving your symptoms is essential before committing to a costly biologic. Take a free, instant, online symptom check to better understand your symptoms and confidently navigate your next steps in care.
Reviewed for medical accuracy: 07/02/2026
Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) affects thousands of people, causing persistent nasal congestion, loss of smell, facial pressure and recurrent infections. Dupixent® (dupilumab) has emerged as an effective biologic therapy to control symptoms and reduce polyp size. However, the cost of Dupixent for CRSwNP can be a barrier. This guide outlines practical steps, assistance programs and resources to help you manage out-of-pocket expenses without increasing stress.
List Price
• Each two-mL syringe of Dupixent has a wholesale acquisition cost of approximately $3,100–$3,200.
• Most patients require one injection every two weeks after an initial loading dose.
Insurance Coverage Variability
• Private health plans, Medicare Part B or D and Medicaid may cover Dupixent differently.
• Coverage depends on formulary status, step-therapy requirements and prior authorization rules.
• Even with insurance, copays or coinsurance can range from $50 to over $1,000 per injection.
Factors Affecting Your Cost
• Plan deductible and out-of-pocket maximum
• Pharmacy benefit manager (PBM) protocols
• In-network vs. out-of-network specialty pharmacies
Sanofi, the manufacturer of Dupixent, offers the Sanofi MyWay® program to help eligible individuals reduce or eliminate copays.
Eligibility Criteria
• U.S. resident with commercial insurance
• Annual household income up to $100,000 (up to $150,000 for multi-person households)
• Confirmation of insurance coverage and FDA-approved indication
Benefits
• Copay assistance up to $10,000 per calendar year
• Coordination with your specialty pharmacy for streamlined billing
How to Apply
If you have limited or no insurance coverage, not all programs may apply. Independent foundations can help cover out-of-pocket costs:
HealthWell Foundation
• Offers grants for biologic therapies, including Dupixent
• Income-based assistance
Patient Advocate Foundation
• Case management and financial aid for copays and deductibles
• Eligibility varies by program
NeedyMeds and RxAssist
• Online directories of assistance programs by medication
• Application guidance
If your insurance plan places Dupixent on a high tier, a savings card from Sanofi can reduce copays:
Verify Formulary Status
• Contact your insurer or PBM to confirm whether Dupixent is on the preferred drug list.
• Ask if prior authorization or step therapy is required.
Use Specialty Pharmacies
• Specialty pharmacies have experience navigating benefit coordination and copay programs.
• They can assist with faster prior authorizations and appeals.
Explore Alternative Coverage
• If uninsured or underinsured, consider state Medicaid programs or Affordable Care Act (ACA) marketplace plans.
• Check if you qualify for Medicare Extra Help (Low-Income Subsidy) to reduce Part D costs.
Request a Financial Navigator
• Many hospitals, clinics and nonprofit organizations employ financial navigators.
• They can guide you through paperwork and identify additional aid.
Mail-Order vs. Retail Pharmacy
• Mail-order specialty pharmacies may offer lower copays for 90-day supplies, if approved.
• Compare costs between local specialty pharmacies and national mail-order options.
Plan for Deductible Seasons
• If you meet your annual deductible early in the year, copays may drop afterward.
• Strategize the timing of your first injection to maximize deductible benefits.
While navigating insurance forms and financial aid can feel overwhelming, take steps to maintain balance:
If your CRSwNP symptoms worsen—such as severe facial pain, sudden vision changes or signs of infection—seek medical attention promptly. If you're experiencing new or changing symptoms and want to better understand what might be happening, try Ubie's free AI symptom checker to get personalized insights and guidance on whether you should seek immediate care or schedule a routine appointment with your doctor.
Understanding the cost of Dupixent for CRSwNP and accessing copay assistance doesn't have to be a solo journey. By leveraging manufacturer programs, independent foundations and strategic planning, you can reduce your financial burden and focus on getting symptom relief.
Always discuss any serious or life-threatening concerns with your doctor. Their guidance is essential in choosing the safest, most effective treatment plan for you.
(References)
* Del Prete, L., Di Perna, G., Passali, G. C., Costi, S., Turetta, V., & Costi, M. (2022). The economic burden of chronic rhinosinusitis with nasal polyps: A systematic review. *Rhinology*, 60(2), 77–90. PubMed: https://pubmed.ncbi.nlm.nih.gov/34293976/
* Schauer, A., White, M., Stull, C., & Yancey, K. S. (2021). Cost-effectiveness of dupilumab for the treatment of chronic rhinosinusitis with nasal polyps in the United States. *Journal of Managed Care & Specialty Pharmacy*, 27(11), 1546–1554. PubMed: https://pubmed.ncbi.nlm.nih.gov/34685718/
* Braddock, J. S., Biskupiak, J. E., & Darden, P. (2020). Patient and Physician Perspectives on Access Barriers to Biologic Therapies for Allergic and Immunologic Diseases. *Journal of Managed Care & Specialty Pharmacy*, 26(10), 1307–1316. PubMed: https://pubmed.ncbi.nlm.nih.gov/33058869/
* Stull, C., Schauer, A., White, M., & Yancey, K. S. (2023). Real-World Healthcare Resource Utilization and Costs for Patients with Chronic Rhinosinusitis with Nasal Polyps in the US. *Journal of Managed Care & Specialty Pharmacy*, 29(4), 408–417. PubMed: https://pubmed.ncbi.nlm.nih.gov/36979219/
* Bachert, C., Pfaar, O., & Mullol, J. (2021). Dupilumab in chronic rhinosinusitis with nasal polyps: A review of its role and value. *Allergy and Asthma Proceedings*, 42(5), 450–459. PubMed: https://pubmed.ncbi.nlm.nih.gov/34521404/
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.